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Abstract
Background: Combination therapy for arterial embolization hyperthermia (AEH) with arsenic trioxide (As2O3) nanoparticles
(ATONs) is a novel treatment for solid malignancies. This study was performed to evaluate the feasibility and therapeutic
effect of AEH with As2O3 nanoparticles in a rabbit liver cancer model. The protocol was approved by our institutional animal
use committee.
Methodology/Principal Findings: In total, 60 VX2 liver-tumor-bearing rabbits were randomly assigned to five groups
(n=12/group) and received AEH with ATONs (Group 1), hepatic arterial embolization with ATONs (Group 2), lipiodol (Group
3), or saline (Group 4), on day 14 after tumor implantation. Twelve rabbits that received AEH with ATONs were prepared for
temperature measurements, and were defined as Group 5. Computed tomography was used to measure the tumors’
longest dimension, and evaluation was performed according to the Response Evaluation Criteria in Solid Tumors. Hepatic
toxicity, tumor necrosis rate, vascular endothelial growth factor level, and microvessel density were determined. Survival
rates were measured using the Kaplan-Meier method. The therapeutic temperature (42.5uC) was obtained in Group 5.
Hepatotoxicity reactions occurred but were transient in all groups. Tumor growth was delayed and survival was prolonged
in Group 1 (treated with AEH and ATONs). Plasma and tumor vascular endothelial growth factor and microvessel density
were significantly inhibited in Group 1, while tumor necrosis rates were markedly enhanced compared with those in the
control groups.
Conclusions: ATON-based AEH is a safe and effective treatment that can be targeted at liver tumors using the dual effects of
hyperthermia and chemotherapy. This therapy can delay tumor growth and noticeably inhibit tumor angiogenesis.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
fatal malignant tumors worldwide [1]. Surgical removal remains the
gold standard for liver cancer. However, the majority of tumors are
inoperable because diagnosis is seldom established in the early
stages [2,3]. Hyperthermia, a therapeutic procedure that raises the
temperature of a tumor, has attracted increasing attention as a
promising approach to cancer therapy [4–6]. The rationale for the
use of hyperthermia is that sustained temperatures above 42.5uC
directly kill living cells. Compared with chemotherapy and
radiotherapy, hyperthermia has fewer side effects.
Transcatheter arterial chemoembolization (TACE) has been
established as a nonsurgical treatment for HCC, and many studies
have established its safety and efficacy, with long-term survival
rates comparable to those seen following surgical resection [2,7].
The rationale for this procedure is that the normal liver
parenchyma receives two-thirds of its blood supply from the
portal vein system, whereas tumors in the liver derive virtually all
of their blood supply from the hepatic arterial system. Thus, for
hepatic tumors, substances injected into the hepatic arterial system
will be preferentially delivered to the liver tumor. This same
principle can be used in arterial embolization hyperthermia
(AEH), which has been used as a localized modality of
hyperthermia for many years and has shown promise in recent
experimental animal studies. In AEH, tumor tissue is heated
specifically, sparing surrounding normal hepatic tissue [8–10].
Arsenic trioxide (As2O3) has been successfully used to treat
patients with acute promyelocytic leukemia [11]. Recent studies
have shown that As2O3 has antitumor activity towards many solid
tumors, including hepatomas [12–14]. Its mechanisms of action
include induction of apoptosis of various cancer cell lines [15],
inhibition of tumor growth [16], and angiogenesis [17].
The purpose of the present study was to evaluate the safety
and the anticancer effects of the useof As2O3nanoparticlescombined
with AEH in established transplanted rabbit VX2 hepatic tumors.
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Technical Success
The TAE and CT procedures were successfully performed in all
animals with the exception of two rabbits. One rabbit in Group 1
died during general anesthetic induction within the scheduled CT
follow-up on day 3 after TAE, and another rabbit in Group 4 died
6 h after a sham procedure on Day 1. Both animals were excluded
from analyses.
Morphology of ATONs
Transmission electron microscopy (Fig. 1) showed ATONs to be
approximately spherical, with diameters of about 40 nm. Imme-
diately after intra-arterial injection (Fig. 2A, B), lipiodol or ATONs
suspended in lipiodol were concentrated in the margin of the
tumor, mainly in vascular channels. Even 2 weeks after intra-
arterial injection, retention of lipiodol or ATONs persisted,
suggesting that clearance of the agent was much faster from
normal liver than from tumors (Fig. 3A–D).
Heating Curve
Intratumor and rim temperatures (Figs. 4A–C) rapidly increased
to 42.5uC within 5 min, and were then maintained above 42.5uC
for 30 min by carefully manipulating the magnetic field intensity.
All nontumor heating levels were safely below 41uC during
treatment. The heating rate was much greater in the center and
periphery of the tumor than in normal hepatic parenchyma
(NHP), and was highest at the rim of the tumor.
Biochemical Tests
Liver function test results (Fig. 5A, B) showed that AST and
ALT levels tended to increase transiently 1 day after intra-arterial
embolization and last for several days following the infusion,
regardless of which agent was administered. Plasma TBil (Fig. 5C),
BUN (Fig. 5D) and Cr (Fig. 5E) levels did not change appreciably
in any group. Elevated AST and ALT levels were transient and
significant (P,0.05) 1 day after intra-arterial embolization and
hyperthermia, but decreased to levels close to normal by 14 days
after intra-arterial embolization. There were no significant
differences in biochemical values among the four groups at days
14 or 21 (P.0.05).
Treatment-associated Tumor Response
The tumor-inhibited effect as evaluated by the Response
Evaluation Criteria in Solid Tumors (RECIST) methodology
[18] at day 21 is shown in Table 1. A gradual decrease of the
tumor’s LD on CT scanning was observed during the following 3
weeks in all Group 1 rabbits treated using AEH with ATONs, and
no tumor recurrence was present on follow-up CT scanning. The
mean LD in Group 1 at 1 and 2 weeks post-treatment was
significantly decreased compared with that in the other three
groups (P,0.05, each; Fig. 5F).
Histopathological Findings
Treated tumors (Figures 6A to C) were considerably smaller
than untreated tumors (Fig. 6D). It was evident that the ATONs
concentrated primarily around the periphery of tumors and were
confined within blood vessels, while only a few penetrated the
central core region, which was poorly vascularized (Fig. 7A).
Massive necrosis and a thick fibrocollagenous capsule around the
tumor, but no viable tumor cells, were seen in the specimen of
AEH plus ATONs obtained on day 7. Adjacent liver parenchyma
appeared normal (Fig. 7B). Tumors in the ATON group (Fig. 7D)
had histological findings similar to those in the AEH plus ATONs
group, except that completely necrotic portions were more
prominent in the AEH plus ATONs group. In the iodized-oil
group, partial necrosis occurred only in the central regions of
tumors (Fig. 7G). In contrast, control tumors showed clusters of
viable tumor cells with lighter regions of necrosis and cellular
debris (Fig. 7H). No ATONs appeared in the lungs or kidneys of
any specimens. Macrophages were associated with occasional
ATONs aggregated in the spleen 14 days after ATON arterial
embolization (Fig. 7I).
Quantitative analysis of microvessels. Quantitative MVD
data from each group are presented in Table 2. A significant
reduction in MVD was noted in Group 1, which was treated with
ATONs plus hyperthermia (Figs. 8A–D).
VEGF expression. In Group 1, plasma VEGF levels were
elevated at day 3 after ATON plus hyperthermia treatment,
followed by a significant decrease through days 7, 10, 14, and 21
(Table 3). Group 1 also had significantly lower VEGF levels in
tumors compared with Group 2 (P=0.003; Table 4). The VEGF-
positive rate was significantly lower in Group 1 than in Group 4
(P=0.0027) or Group 3 (P,0.001). The difference between
Groups 1 and 2 was not statistically significant (Table 4, Fig. 8E–
H).
Tumor necrosis. The mean tumor necrosis rates of the
tumors in each group are given in Table 2. The ATON plus
hyperthermia group (Group 1) showed the highest tumor necrosis
rates (P,0.001).
Survival
All rabbit deaths during the course of the study were caused by
hepatic and/or respiratory failure secondary to extensive tumor
burden. All of these events occurred within 57 days, reflecting the
aggressive nature of this tumor model.
Even though no rabbits were completely cured, animals in the
AEH plus ATON group survived significantly longer than did the
controls (Kaplan-Meier method with log-rank test, P,0.001;
Fig. 9).
Discussion
Although currently available TACE may result in a modest
improvement in HCC patient survival, a radiological complete
response is achieved in only 35% of patients according to EASL
Figure 1. TEM micrographs of ATONs. Transmission electron
microscopy showed ATONs to be approximately spherical, with
diameters of about 40 nm.
doi:10.1371/journal.pone.0017926.g001
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[20,21]. However, eligible patients have already benefited from
available hyperthermia technologies [22,23] including radiofrequency,
which heats not only the tumor but also the surrounding healthy tissue.
Another limit of radiofrequency is the cooling effect of the intact blood
supply [8], which results in nonuniform heating of the target area.
Thus, development of more effective therapies is urgently needed.
AEH is based on using the arterial supply of a tumor to provide
a pathway for selective embolization of the tumor by using
magnetic particles, followed by exposure to an alternating
magnetic field to generate heating of the embolized particles by
hysteresis or Ne ´el relaxation. Briefly, Ne ´el loss is caused by the
relaxation of magnetization vector rotation of single-domain
magnetic particles in an applied AC field, while hysteresis loss is
heat loss caused by the magnetic properties of the armature.
As2O3 is currently being tested against various malignancies,
including HCC [11–14,24,25]. However, its clinical application is
limited by its narrow therapeutic window. Alternatively, ATONs
deliver local treatment and potentially achieve therapeutic efficacy
by improving tumor/normal tissue uptake ratios; furthermore, they
avoid toxicity by reducing uptake of ATONs by nontarget organs
[26]. Both the antivascular effects and direct cellular thermo-
sensitization of As2O3 contributed to the increase in heat-induced
tumor growth delay observed in these studies [24]. As2O3 reduces
the blood flow in vivo and prolongs the dwell time of the drug within
the tumor, and preferential uptake of iodized oil would be expected
to increase the amount of drug directed at the tumor [27]. Thus, we
believe that ATONs combined with AEH could exert a synergistic
antitumor effect via two properties: chemotherapy of As2O3 and
thermotherapy of magnetic Fe2O3 nanoparticles.
Our hyperthermia system consists primarily of a ferrite-core
applicator with an aperture with a 350-mm vertical distance, 300-
mm length, and 200-mm width (large enough to accommodate a
rabbit or even larger animals). The device is operated at a frequency
of80 kHz,andthefieldstrengthcan beadjustedfrom5to10 kA/m.
Our hyperthermia system can generate high temperatures. To
determine the possibility of using either AMFor lipiodol in heating,a
preliminary experiment was performed with another group of
animals using saline or lipiodol. A FISO probe was introduced into
the tumor, showing that the AMF was activated; we had to exclude
the possibility that the magnetic field itself was contributing to any
change in temperature or tumor growth (data not shown).
Figure 2. Representative rabbit hepatic angiographic images. Figure 2A Selective placement of 3F microcatheter (white arrow) and injection
of ATONs suspended in lipiodol in the proper left hepatic artery revealed ill-defined hypervascularity tumor staining in the left lobe. Figure 2B
Postembolization images show complete stasis of blood flow and demonstrate dense staining of the tumor bed, suggesting successful delivery and
excellent distribution of the magnetic nanoparticle fluid mixture in the tumor.
doi:10.1371/journal.pone.0017926.g002
Figure 3. Serial CT imaging findings after TAE. Figure 3A CT scan obtained immediately after TAE. ATONs have accumulated primarily in the
tumor (black arrow), whereas ATON retention in the NHP region (white arrow) is minimal. Figure 3B CT scan obtained 3 days after TAE shows ATONs
retained in the tumor (black arrow). The number of ATONs within the NHP region is decreasing. Figure 3C Seven days after TAE (4 days after AEH),
ATONs are selectively retained in the tumor (black arrow), whereas they are barely visible within the NHP region. Figure 3D Fourteen days after TAE
(11 days after AEH), ATONs are still observed in the tumor region, and have especially accumulated in the peripheral area.
doi:10.1371/journal.pone.0017926.g003
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the potential of various magnetic nanoparticles, including maUgU-
netitecationic liposomes, c-Fe2O3,a n dF e 3O4 inAEH.Our study is
the first report on the therapeutic effects of ATONs in an animal
HCC tumor model. In a previous study, we evaluated the different
heating abilities of c-Fe2O3 nanoparticles and ATONs. The
magnetic properties of the nanoparticles were shown in a hysteresis
loop (Fig. S1), which indicated that c-Fe2O3 had a higher specific
absorption rate (21.4610
3 W/kg Fe) than ATONs (18.2610
3 W/
kg Fe) under an alternating current magnetic field of 10 kA/m and
80 kHz. However, both nanoparticles achieved therapeutic tem-
peratures in the in vivo experiment.
Our self-prepared ATONs combined with hyperthermia had a
significant therapeutic effect on VX2 liver cancers. Tumor growth
was delayed, angiogenesis was inhibited, survival time was prolonged,
and side effects were endurable. Our promising results are consistent
with and extend a previous study [31], which showed that a
combination of nanosized As2O3/Fe2O3 complexes has a substan-
tially greater inhibitory effect than either agent alone. The findings
from our present study may be explained by synergy between ATON
embolization and hyperthermia. ATON embolization is able to block
the flow of blood to a tumor, reduce tumor perfusion, and decrease
heat dissipation [24,25], which further enhances the hyperthermic
therapeutic effect, and inhibit angiogenesis [17,32]. The antiangio-
genic effect of ATON embolization plus hyperthermia was
demonstrated by quantitative MVD analysis and ELISA analysis of
decreased VEGF expression in tumors and plasma.
Our results indicate that AEH using ATONs can specifically
heat tumor tissue without damaging adjacent healthy tissue. It has
been demonstrated that tissue iron concentrations are linearly
related to heating rates [9,27]. In our study, the higher
concentration of ATON embolization in the highly vascularized
tumor rim (Fig. 7A) compared with that in the poorly vascularized
tumor core led to higher temperatures in the tumor rim than in the
tumor core or normal tissue (Fig. 4). This targeted hyperthermia
was due to two factors. First, infusion of the embolized agent into
the hepatic arterial system resulted in the deposition of ATONs
throughout the tumor, excluding regions of necrosis, thereby
targeting the tumor and largely sparing NHP. Second, the half-life
of lipiodol is greater in a tumor than in NHP. The significantly
elevated temperature at the core of tumors was not surprising. The
blood vessels of tumors are dilated, tortuous, and without complete
basement membranes. Furthermore, venous drainage of tumors is
often chaotic and incomplete [8]. These factors are likely to result
Figure 4. Temperature profiles during AEH treatment. Figure 4A Typical heating curve for the temperature of the tumor core, rim, normal liver
tissue, and rectum of Subject 1 in Group 5, from baseline to temperature during AEH treatment. Figure 4B Typical mean heating curve for the
temperature of each subject in Group 5 during AEH treatment. Intratumor and rim temperatures increase rapidly to 42.5uC within 5 min and are then
maintained above 42.5uC for 30 min, while the temperature inside NHP and the rectum remain below 40uC. Figure 4C Intratumor and rim delta
temperature changes show the specific heating of the tumor during treatment.
doi:10.1371/journal.pone.0017926.g004
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poorer blood perfusion (as a result of the absence of an ordered,
high-flow, portal venous system) within the necrotic regions of
tumors. Poorer blood flow through the center of tumors may favor
the flow of heat into the tumor core from the hotter rim. Previous
results [33] support this assertion.
The distribution and clearance of ATONs are important issues
for the potential clinical application of ATONs. We injected
ATONs into the hepatic artery; most ATONs went to targeted
liver tumors. ATONs deposited in either normal liver or tumor
tissue were still clearly visible on CT images or pathology slices
several weeks after ATON injection. The long deposition time of
ATONs in NHP may lead to unexpectedly high temperatures in
healthy tissue during treatment. However, clearance of ATONs
was much faster from tumors than from NHP. Therefore, we
implemented hyperthermia 3 days after TAE. This reduced the
potential threat of liver dysfunction in rabbits treated with TAE
plus hyperthermia. However, in a clinical setting, superselective
catheterization of the tumor-feeding artery could be performed
before arterial embolization and hyperthermia, which would spare
as much normal liver tissue as possible and reduce ATON
deposition, thus preventing this potential complication. On the
other hand, sparse distribution of ATONs in NHP cannot be
avoided, but the large portal blood flow would cool these point
sources of heat and thus prevent thermal damage to NHP. Our
results demonstrate that the temperature of NHP remained at safe
levels (below 41uC) during treatment. Furthermore, our results are
consistent with those of Moroz et al. [9], who showed that the lack
of a raised temperature in the rectum indicates that no significant
body core heating has occurred. This indicates that either no
ATONs passed through the hepatic circulation into the systemic
circulation or no significant nonhepatic tissue heating occurred.
Histological analysis of lung and kidney tissues failed to show
evidence that ATONs passed through the liver and lodged within
the lungs or kidneys. The finding of ATON aggregates within
macrophages in the liver and spleen suggests that ATONs may be
eliminated from the liver and spleen over time. Examination of
splenic tissue (day 14) revealed some macrophages in association
with ATONs, while splenic tissue at days 1, 3, and 10 failed to
show them, presumably indicating that ATONs were not removed
by macrophages before day 14 after TAE. This may be an
advantage, because this time interval allows for a sufficient number
Figure 5. Biochemical tests and antitumor effect. Figure 5A and B The diagram shows ALT level changes in groups 1 to 4. ALT levels tended to
increase significantly more in Group 1 than in the other groups 1 day after the animals were subjected to hyperthermia, but gradually decreased. AST
levels changed in the same manner as did ALT levels. Figure 5C Plasma TBil levels did not change appreciably in any group. Figure 5D and E The renal
function test, in which the plasma BUN and Cr values were detected, showed no statistically significant differences among the groups. Figure 5F
Antitumor effect evaluated by the tumor long-axis dimensions in both the control and treatment groups. During the experimental period, the mean
LD decreased significantly more in groups 1 and 2 than in the other two groups.
doi:10.1371/journal.pone.0017926.g005
Table 1. Tumor Response by RECIST criteria.
Tumor Response
Complete Response (%) Partial Response (%) Stable Disease (%) Progressive Disease (%)
Group1(n=7) 0 7(100) 0 0
Group2(n=8) 0 4(50) 4(50) 0
Group3(n=7) 0 2(28.5) 2(28.5) 3(43)
Group4(n=8) 0 0 0 8(100)
doi:10.1371/journal.pone.0017926.t001
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necrosis in VX2 liver tumors treated with ATON embolization plus hyperthermia (A) and with ATON embolization alone (B). C: Lipiodol embolization
resulted in significantly (P,0.05) larger tumors than those of groups 1 or 2 at day 14. D: Gross pathologic specimens of a tumor from an NS control
rabbit (Group 4), showing a solitary mass (T) and intrahepatic metastasis (M) at the time of death.
doi:10.1371/journal.pone.0017926.g006
Figure 7. Representative histopathological (H&E) findings. Figure 7 A–I A: Original magnification: H&E, 1006. Section of a VX2 liver tumor
treated with AEH mediated by ATONs (A) at the periphery, which was surrounded by NHP (H). A necrotic central core (N) is surrounded by an area of
debris, inflammatory reaction, and fibrosis. B: Original magnification: H&E, 1006. Section through NHP 7 days after arterially embolized ATONs. The
liver architecture is preserved. C: For each H&E histological image, both an outer tumor border (red line) and inner regions of necrosis (green line)
were manually circumscribed to permit reference-standard histopathology-based necrosis-rate measurements. Original magnification: H&E, 256.D :
Original magnification: H&E, 1006. Microscopic image in Subject 4 from Group 2 treated with ATON embolization, showing ATONs deposited within
the vascular system. Three days after embolization, an area of necrosis together with inflammatory cell infiltration and extensive fibrosis surrounding
the necrotic area were evident. The area of necrosis was not as extensive as in Group 1. E: Original magnification: H&E, 1006. Pathological specimen
from a rabbit in the hyperthermia group shows massive necrosis of the tumor and aggregates of ATONs that have embolized within the vascular
system of the tumor. The VX2-implanted region in the liver has been replaced by scar tissue. Histological changes include hemorrhage, chronic
inflammation, and necrosis. No viable tumor cells are evident in either the rim or center of the tumor. F: Original magnification: H&E, 2006. ATON
aggregates confined within a blood vessel, surrounded by necrotic tumor cells 14 days after ATON arterial embolization. The tumor cells in the
treated animal appear shrunken, and their nuclei are pyknotic. G: Original magnification: H&E, 1006. H&E-stained micrograph of a lipiodol-treated
tumor at day 7 showing the presence of damaged tumor cells; note the intermixed areas of clearly viable tumor (V), indicating potential spread of the
tumor beyond its circumscribed boundary. H: Original magnification: H&E, 1006. H&E-stained section of tumor from a control rabbit (Group 4) shows
areas of viable tumor (V). I: Original magnification: H&E, 2006. Macrophages associated with ATON aggregates (black arrow) in the spleen 14 days
after ATON arterial embolization.
doi:10.1371/journal.pone.0017926.g007
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We believe that it represents an important prerequisite for the
clinical application of this technique in liver cancer.
AEHhasnotyetbeentestedinhumans,andtheclinicallyrelevant
dosage remains largely unknown. The net c-Fe2O3 dose (21.2 mg/
kg body weight) applied in our regional procedure was similar to
those of previous preclinical hyperthermia studies, which showed
effective inhibition of tumor growth by hepatic arterial administra-
tion of nanoparticles at doses of 25–100 mg in each rabbit with
hepatic orthotopic VX2 carcinoma [8,9,27]. On the other hand, the
net As2O3 dose (2.8 mg/kg body weight) applied in our study was
clearly within the dose range of previous studies, which used As2O3
to treat experimental solid tumors after single or multiple doses
of 1–10 mg/kg [16,24,25,34–40]. However, such doses are
considerably higher than the daily dose of 0.16–0.24 mg/kg
given for several weeks in a recent phase II clinical trial, which
was not active against advanced HCC [41]. Our doses were chosen
ontheassumptionthatahumanliverweighs15timesthatofarabbit
liver (1500 g compared with 100 g) [8,9]. Thus, doses of 24 mg/kg
ATONs (0.3 mL suspension/kg, total 0.9–1.2 mL/rabbit) in a
rabbit would be equivalent to a total of 13.5–18 mL of ATON
suspension in a human subject. These volumes are comparable with
those currently used in TACE. In TACE, up to 20 mL of lipiodol
containing a chemotherapeutic agent may be used to embolize liver
tumors via the hepatic arterial system. Although the present
preliminary study has shown promising results, the optimal ATON
dose that is appropriate for human investigations is unclear at this
time, and further studies are needed.
Our study has several limitations. First, in terms of the diameter
and dosage of ATONs, the power of the magnetic induction field,
and the duration of heating, our in vivo experiments were conducted
under only one set of conditions. Second, the therapeutic effect of
ATONs was not compared with that of other chemotherapy drugs or
other magnetic nanoparticles. Third, we did not investigate the
circulationofATONs in the blood. However, on the basis ofexcellent
tumor targeting, local arterial embolization could guarantee an
increase in the local tumor concentration of ATONs while reducing
the amount of circulating ATONs. Despite these limitations, our
preliminary study demonstrated that AEH mediated by ATONs has
a sound theoretical basis, and it produced some encouraging results
that could ultimately be integrated into clinical practice.
Conclusions
AEH with ATONs inhibited tumor growth in most treated
animals with temporal hepatic dysfunction, and significantly
improved survival in the intrahepatic VX2 tumors in our study.
The therapeutic effect of AEH may be further enhanced when it is
combined with ATONs, the antitumor effects of which are partly
due to inhibition of tumor angiogenesis but also correlated with
altered VEGF expression in the tumor and plasma. Further studies
aimed at elucidating the optimal dose and mechanism in animals,
and ultimately clinical trials, are required.
Figure 8. Immunohistochemical staining for CD31 and VEGF. Representative immunohistochemical staining with CD31 and VEGF
monoclonal antibodies in VX2 liver tumors in each group. Microvessels are identified by dark brown (original magnification, 2006). A marked
reduction in MVD is observed in the ATON plus hyperthermia group (A) and ATON embolization alone group (B). Abundant microvessels are evident
in both the lipiodol TAE group (C) and NS control group (D). Positive VEGFs are recognizable as intensely stained in tumor cell cytoplasm (original
magnification, 2006). It is evident that the abundance of VEGF-positive tumor cells is higher in the lipiodol TAE group (G) and NS control group (H)
than in the ATON plus hyperthermia group (E) or ATON embolization alone group (F).
doi:10.1371/journal.pone.0017926.g008
Table 2. MVD and Mean Tumor Necrosis Ratios in Different
Groups.
Group
Mean necrotic area ratios
(%) (mean±SD) MVD (mean±SD)
1(n=4) 92.0862.62
a,b,c 17.9565.44
g,h,i
2(n=4) 84.0064.75
d,e 32.8567.53
j,k
3(n=4) 59.75610.59
f 76.30619.16
4(n=4) 44.63610.96 63.05611.20
Mann-Whitney U Test:
a:G1 vs. G2 p=0.000;
b: G1 vs. G3 p=0.000;
c: G1 vs. G4 p=0.000;
d:G2 vs. G3 p=0.000;
e: G2 vs. G4 p=0.000;
f: G3 vs. G4 p=0.000;
g:G1 vs. G2 p=0.000;
h: G1 vs. G3 p=0.000;
i: G1 vs. G4 p=0.000;
j:G2 vs. G3 p=0.000;
k: G2 vs. G4 p=0.000.
doi:10.1371/journal.pone.0017926.t002
Arterial Embolization Hyperthermia on Hepatoma
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17926Materials and Methods
Animal Models and Groups
All animal procedures were performed in accordance with the
approval and guidelines of the Institutional Animal Care and Use
Committee (IACUC) of the Medical School of Southeast
University (approval ID: SYXK-2007.2121).
Sixty male New Zealand white rabbits (provided by Southeast
University, Nanjing, China) were randomly assigned to five groups
(n=12 each; Fig. 10). An orthotopic model of hepatocarcinoma
was developed using VX2 carcinoma as described previously [42].
The animals from each group received a hepatic arterial infusion
of arsenic trioxide (As2O3) nanoparticles (ATONs) (Groups 1, 2,
and 5), lipiodol (Group 3), or saline (Group 4). In Groups 1 and 5,
hyperthermia was induced on day 3 after transcatheter arterial
embolization (TAE). Four rabbits from Groups 1 to 4 were
sacrificed on day 7 for histopathological examination after TAE,
whereas the remaining eight animals in each group were kept for
the survival study. Animals in Group 5 were used for dynamic
measurement of temperatures during the hyperthermia procedure,
and were serially sacrificed at 1, 3, 10, and 14 days after TAE
(three rabbits each day) to verify the distribution of ATONs.
Treatment Procedure, Temperature, and Tumor
Response Measurement
TAE was performed (H.Y., G.Y.Z.,) at 14 days after tumor
implantation using an angiography system (Innova 3100, GE
Medical Systems, Milwaukee, WI, USA) according to a method
described previously [43]. Briefly, using an aseptic technique, the
Table 3. Plasma VEGF Levels in Different Groups.
Group Plasma VEGF Level (pg/ml)
Day 0 Day 3 Day 7 Day 10 Day 14 Day 21
1 64.95619.98 95.00640.10
b 58.37621.19
b,c 49.40620.03
b,c 38.33617.86
b,c 29.2168.18
a,b,c
(n=8) (n=7) (n=7) (n=7) (n=7) (n=7)
2 67.01619.29 98.08631.47
d 70.13630.39
d 54.89620.52
d,e 45.69615.96
d,e 44.56613.79
d,e
(n=8) (n=8) (n=8) (n=8) (n=8) (n=8)
3 62.54620.26 159.67648.23
f 176.54627.57
f 166.67638.12
f 95.48631.19
f 83.94617.99
f
(n=8) (n=7) (n=7) (n=6) (n=6) (n=5)
4 63.10620.51 71.24620.96 88.38627.78 122.93618.44 172.97630.60 298.00679.37
(n=8) (n=8) (n=8) (n=7) (n=6) (n=3)
Mann-Whitney U Test:
a:G1 vs. G2 p=0.021;
b: G1 vs. G3 p,0.05;
c:G1 vs. G4 p,0.05;
d:G2 vs. G3 p,0.05;
e: G2 vs. G4 p,0.05;
f:G3 vs. G4 p,0.05.
doi:10.1371/journal.pone.0017926.t003
Table 4. Comparisons of Tissue VEGF levels at Day 7 between groups.
Group
Tissue VEGF at Day 7
(mean±SD)pg/mg protein
VEGF expression at day 7
(10 sections/Tumor) Positive Rate(%)
2 ± +
1(n=4) 30.0567.12
a,b,c 32 5 3 8/40 (20%)
g,h,i
2(n=4) 41.2269.25
d,e 28 5 7 12/40 (30%)
j,k
3(n=4) 97.64617.31
f 28 5 7 34/40 (85%)
l
4(n=4) 60.85611.16 18 16 6 22/40 (55%)
Abbreviations: 2(negative); 6(weakly positive);+(positive).
Mann-Whitney U Test:
a:G1 vs. G2 p=0.003;
b: G1 vs. G3 p=0.000;
c: G1 vs. G4 p=0.000;
d:G2 vs. G3 p=0.000;
e: G2 vs. G4 p=0.000;
f: G3 vs. G4 p=0.000.
Chi-square test:
g:G1 vs. G2 p=NS;
h: G1 vs. G3 p=0.000;
i: G1 vs. G4 p=0.0027;
j:G2 vs. G3 p=0.000;
k: G2 vs. G4 p=0.0418;
l: G3 vs. G4 p=0.0073.
doi:10.1371/journal.pone.0017926.t004
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pentobarbital at 4 mL/kg intravenous infusion, Shanghai Chem-
ical Reagent Co., Shanghai, China) was accessed via surgical
cutdown and a 4F vascular sheath was placed (Terumo, Tokyo,
Japan). Selective catheterization of the proper hepatic artery
feeding the VX2 carcinoma was performed using a 3F micro-
catheter (SP, Terumo, Tokyo, Japan), which was coaxially inserted
through a 4F Cobra catheter (Cook Inc., Bloomington, IN, USA)
with fluoroscopic guidance. Hepatic angiography was obtained
with hand injection of 3 mL of contrast medium (Omnipaque 300;
Figure 9. Kaplan-Meier survival analysis of liver-tumor-bearing rabbits. Graph of the Kaplan-Meier method with the log-rank test shows a
significant survival benefit for the animals treated with ATON embolization alone or plus hyperthermia compared with those in Groups 3 and 4.
doi:10.1371/journal.pone.0017926.g009
Figure 10. Flow chart of the experiment. Flow chart of the experiment and diagram showing experimental groups according to the
embolization agents that were used for intra-arterial delivery.
doi:10.1371/journal.pone.0017926.g010
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at a rate of approximately 0.5 mL/s.
As2O3 nanoparticles (ATONs; approximately 40 nm in diame-
ter; 88.50% (wt/wt) c-Fe2O3 Hcore coated withH 11.50% (wt/wt)
As2O3) were made in our laboratory according to a method
described previously [31,44]. A thin layer of ATONs was spread
and exposed to ultraviolet light for sterilization. The ATONs were
then magnetically separated and quantitatively dissolved in lipiodol
(Laboratoire Guerbat, France; 80 mg ATONs/1 mL lipiodol) via
ultrasonography.
After the desired ATON suspension dose (24 mg ATONs,
including net c-Fe2O3 21.2 mg plus net As2O3 2.8 mg per kg body
weight) had been carefully infused through the 3F microcatheter
into the tumor-feeding artery, the femoral artery was ligated and
the wound was closed. Selective catheterization of the tumor-
feeding artery under a DSA monitor guaranteed tumor target
embolization and spared arterial flow through the hepatic artery
into the liver.
Three days after TAE, using the general anesthesia protocol
and aseptic technique described above, a puncture needle (18G,
Terumo, Tokyo, Japan) was percutaneously advanced into the
center or the rim of the tumor, the normal liver 1 cm from the
tumor rim, and the rectum, under CT guidance (Fig. 11). The
needle stylet was then replaced with a fiberoptic temperature
probe (FISO Inc., Quebec, QC, CA). This CT-guided percuta-
neous puncture and temperature measurement technique mini-
mized potential heat loss to the external environment. Animals
were subjected to the AEH therapy system (Figs. 12A, B) described
previously (frequency, 80 kHz; field strength, 5–10 kA/m) [28,29].
Each probe tip temperature, wattage, field intensity, and
frequency was recorded during the procedure. After the tumor
core temperature had reached the intended temperature (42.5uC),
it was maintained at 42–45uC for a period of 30 min by manually
adjusting the magnetic field strength. The temperature of the liver
itself was maintained at approximately 37.8uC.
Plain CT scanning was performed to evaluate the ATON
distribution and each tumor’s longest dimension (GE HiSpeed
CT/i Scanner, GE Medical Systems, Milwaukee, WI, USA) at
days 0, 3, 4, 7, 10, 14, and 21 with parameters of 120 kV,
200 mA, FOV 16 cm, slice thickness 3 mm, pitch 1.5 mm,
reconstruction 2 mm, and matrix 512.
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria were used to determine objective responses to treatment
[18,45,46]. A complete response (CR) was defined as the
disappearance of all lesions with no new lesion development; a
partial response (PR) as a decrease of 30% or more in the longest
dimension (LD) or the sum of the longest dimensions of all
measured target lesions; stable disease (SD) as any change in tumor
size that did not satisfy PR or PD criteria; and progressive disease
(PD) as an increase of .20% in the longest dimension or the sum
of the longest dimensions of all measured target lesions or any new
lesion. All CT images were blindly analyzed by two radiologists
(Q.L. and H.Z.N., who had 15 and 12 years of experience,
respectively) by consensus.
Biochemical Studies and Vascular Endothelial Growth
Factor Assay
Peripheral blood samples (2.0 mL) were collected for biochem-
ical examination at days 0, 3, 4, 7, 10, 14, and 21 after treatment.
Plasma aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), blood urea nitrogen (BUN), Hserum creatinineH (Cr),
and total bilirubin (TBil) levels were measured using a biochemical
autoanalyzer (Model LX 20; Beckman, CA, USA).
The tumor tissues were prepared as described previously [47].
Vascular endothelial growth factor (VEGF) levels of plasma and
tumor tissue were measured using an ELISA assay (Rapid Bio,
CA, USA) according to the manufacturer’s instructions. Each
sample was measured in triplicate.
Histopathological and Immunohistochemical
Examinations
The animals were sacrificed by intravenous injection of an
overdose of sodium pentobarbital at the defined endpoint. The
intact liver, lungs, kidneys, spleen, and any metastases were
removed and fixed in 10% buffered formalin, and were then
carefully sectioned in 4-mm-thicknesses in the axial plane to
correspond with the plane of the CT scan. All paraffin-embedded,
hematoxylin and eosin (H&E)-stained sections were examined
microscopically.
To assess VEGF expression, 10 random non-necrotic areas
(6200) from each specimen were evaluated [48] using a VEGF
monoclonal antibody (Santa Cruz Biotechnology Inc., CA, USA).
Experiments were performed according to the supplier’s instruc-
tions. VEGF expression was semiquantitatively evaluated at three
levels: positive staining in less than 10% was regarded as negative
(2), positive staining in 10–50% as weakly positive (6), and
positive staining in 50% or more as positive (+) [49]. For
determination of MVD, paraffin-embedded sections were stained
with an anti-CD31 rabbit monoclonal antibody (DAKO Corp.,
Carpinteria, CA, USA) following a standard SABC procedure,
according to a method described previously [50]. Briefly, five fields
of ‘‘vascular hot spots’’ with a 200-fold magnification in each
tumor section obtained at 7 days after TAE were examined, and
the mean MVD value was recorded in a blinded fashion. The
percentage of the necrotic area in the entire tumor area was
calculated from H&E sections according to a method described
previously [30].
Figure 11. CT-guided percutaneous puncture to monitor
temperature changes. Under CT-guided percutaneous puncture,
implantation of three 18G puncture needles and replacement of FISO
probes using the coaxial method were performed. The probes were
located in the core (C), rim (R), and NHP (N) 1 cm away from the rim to
monitor temperature changes in real-time, and the animals were
subsequently transferred to AMF for hyperthermia.
doi:10.1371/journal.pone.0017926.g011
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microscope (ZEISS, Germany) equipped with an Axiocam MR5
digital camera and Image-Pro Plus version 6.0 (Media Cybernet-
ics, Silver Spring, MD). An experienced pathologist (Z.Y.W) who
was blinded to the experiment details evaluated all specimens.
Statistical analyses
Statistical evaluation was performed using SPSS software (ver.
13.0; SPSS Inc., Chicago, IL, USA). Numerical data were
expressed as means6SD. A P value,0.05 was considered to
indicate statistical significance. The Kruskal-Wallis and Mann-
Whitney U tests were performed among groups. Survival rates
were assessed using the Kaplan-Meier method.
Supporting Information
Figure S1 The magnetic properties of c-Fe2O3 nanopar-
ticles and ATONs. The magnetic properties of c-Fe2O3
nanoparticles and ATONs were shown in a hysteresis loop
according to a method described previously [28,29], indicating a
higher specific absorption rate of c-Fe2O3 nanoparticles than of
ATONs under an alternating current magnetic field of 10 kA/m
and 80 kHz.
(TIF)
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